


Supplementary Figure 1. Indexes at the start and after 3 months of nilotinib therapy.

(A) **HOMA2-IR index** [reflecting hepatic insulin resistance]; (B) **Insulin sensitivity index (HOMA2-%S)** derived from the HOMA2 calculation as percentages of a normal reference population; (C) **ISI_{0.120} or Gutt index** [tends to reflect peripheral insulin resistance and correlates with euglycemic clamp]; (D) **Steady state β -cell function (HOMA2-%B)** derived from HOMA2 as percentages of a normal reference population.

Supplementary Figure 2. Change in β -cell function based on the HOMA2-%B difference (**HOMA2-%B_{3month} – HOMA2-%B_{start}**) at the start and the 3rd month of nilotinib therapy in 2 patients who fulfilled criteria of diabetes mellitus (DM) during nilotinib treatment compare to the 8 other patients.

Supplementary Figure 1.



Supplementary Figure 2.

